International Psoriasis Council
Advancing Knowledge. Improving Care.
At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and treatment. Highlights include
IPC’s 2025 SID Congress Report highlights the most impactful psoriasis sessions, covering novel cell-biology insights, neuroimmune mechanisms, metabolic and senescence
Discover the new free psoriasis course on WHOAcademy, created by IPC and IFPA for the WHO. Enhance your knowledge of
The Psoriasis: From Gene to Clinic Congress Report highlights breakthroughs in genetics, clinical care, and treatment advancements for psoriasis, featuring
The 2024 IPC Think Tank Congress Report provides a comprehensive summary of key topics, including the epidemiology of psoriasis, genetic
The 2024 Society for Investigative Dermatology (SID) Annual Meeting was held from May 14 to 18, 2024, in Dallas, Texas,
Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about
Discover the latest updates on psoriasis from the World Congress of Dermatology (WCD) 2023, hosted in Singapore from July 3–8.
The International Society of Investigative Dermatology (ISID) held its inaugural meeting in Tokyo, Japan, from May 10 – 13, 2023.
The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve
New resource page that includes the latest articles, downloads, and related press releases on GPP to assist with diagnosing and
Prof. van de Kerkhof provides a review of a recent publication by Paulo Gisondi from Verona on the risk of
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.